Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline and Imiquimod for CTCL
NCT03116659Phase 1Unknown
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doxycycline and imiquimod in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoint: Pilot assessment of response at 1 year. Status: unknown.
02
Drugs
doxycyclineimiquimod
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03116659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116659.